National assessment of margin status as a quality indicator after pancreatic cancer surgery.

Item

http://www.wikidata.org/entity/Q38171293

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

National assessment of margin ...... ter pancreatic cancer surgery.

@en

type

Item

label

National assessment of margin ...... ter pancreatic cancer surgery.

@en

prefLabel

National assessment of margin ...... ter pancreatic cancer surgery.

@en

P1476

National assessment of margin ...... ter pancreatic cancer surgery.

@en

P2093

Clifford Y Ko

http://www.w3.org/2001/XMLSchema#string

David J Bentrem

http://www.w3.org/2001/XMLSchema#string

David P Winchester

http://www.w3.org/2001/XMLSchema#string

Henry A Pitt

http://www.w3.org/2001/XMLSchema#string

Karl Y Bilimoria

http://www.w3.org/2001/XMLSchema#string

Mitchell C Posner

http://www.w3.org/2001/XMLSchema#string

Ryan P Merkow

http://www.w3.org/2001/XMLSchema#string

P2860

Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al.

The National Cancer Data Base: a powerful initiative to improve cancer care in the United States

Principles of multilevel modelling.

Physician cost profiling--reliability and risk of misclassification

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

An anatomical-based mapping analysis of the pancreaticoduodenectomy retroperitoneal margin highlights the urgent need for standardized assessment.

Assessment of pancreatic cancer care in the United States based on formally developed quality indicators.

Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.

Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial.

Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival.

P2888

s10434-013-3338-2

P304

1067-1074

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-013-3338-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Timothy Pawlik

P577

2013-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1028471604

http://www.w3.org/2001/XMLSchema#string

P698

24337612

http://www.w3.org/2001/XMLSchema#string